A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)
Clinical trial NCT06112275 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06112275
- Sponsor
- Encoded Therapeutics
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-28
- Primary completion
- 2030-09-01
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.